FDA to consider expanding access to certain peptides for compounded medications

The FDA will review whether to allow compounding pharmacies greater access to certain peptides for customized medications. This decision could impact treatments for various conditions. The review focuses on seven peptides currently restricted due to safety concerns, with an advisory panel meeting in late July. Health Secretary Robert F. Kennedy Jr. supports expanding access. Some scientists express caution due to limited data on the safety and efficacy of these peptides, especially in mixtures promoted online.